committed to research and innovation
Transcription
committed to research and innovation
IIB Sant Pau, committed to research and innovation Sant Pau Biomedical Research Institute The Sant Pau Biomedical Research Institute (IIB Sant Pau) conducts high-level basic, clinical and epidemiological and healthcare research aimed at improving the quality of life of patients. IIB Sant Pau aims to become an international centre of excellence in translational research and innovation. In terms of its potential to do so, solid foundations have already been laid, as the Hospital de la Santa Creu i Sant Pau (HSCSP) is the fifth hospital in Spain in terms of scientific productivity, with notable achievements in terms of prestigious publications and international cooperation agreements. WHAT IS © Sant Pau Biomedical Research Institute Edition and design Corporate Communications and Public Relations Department of the Hospital de la Santa Creu i Sant Pau v2 - January 2012 IIB SANT PAU? IIB Sant Pau was founded in 2009 as an association between ten healthcare bodies carrying out their own research. Three of these bodies correspond to the HSCSP, namely, the HSCSP Healthcare Management Foundation, the HSCSP Private Foundation and the Research Institute. The other seven entities are the Catalan Institute of Cardiovascular Sciences (ICCC), the Puigvert Foundation, the Blood and Tissue Bank, the Iberoamerican Cochrane Centre, the Ageing Institute of the Autonomous University of Barcelona (UAB), Barcelona-Sardenya Primary Care Centre and the Public Health Agency of Barcelona. In 2010, IIB Sant Pau was formally accredited as an approved healthcare research body by the Spanish Ministry of Science and Innovation. This approval, representing external recognition of research excellence, means that IIB Sant Pau is included in a network of research institutes within the Spanish national healthcare system. HSCSP Healthcare Management Foundation: Manages the care, teaching and research activities of the HSCSP. Research Institute: Publicises and promotes HSCSP research. Institut de Recerca HSCSP Private Foundation: Owns and safeguards the HSCSP historical and other premises and buildings. Ageing Institute-UAB: Generates and manages knowledge aimed at improving the quality of life of the elderly. The institute is attached to the UAB, a vanguard biomedical teaching and research university. Catalan Institute of Cardiovascular Sciences (ICCC): Conducts basic and clinical research into cardiovascular diseases. Puigvert Foundation: Conducts studies and generates knowledge regarding urinary and male reproductive system disorders and dysfunctions and their treatment. IIB SANT PAU ENTITIES Iberoamerican Cochrane Centre: Promotes medical practice based on the best scientific evidence available. Barcelona-Sardenya Primary Care Centre: Conducts research into clinical trials and epidemiology studies as part of the Spanish national healthcare system. Public Health Agency of Barcelona (ASPB): Conducts health status and policy analysis studies for the population in its catchment area. Blood and Tissue Bank: Specialises in transfusion medicine and tissue storage. IIB Sant Pau’s mission is to manage, promote, undertake and publicise research in the health sciences by: • Promoting knowledge exchange between researchers. • Publishing scientific advances and breakthroughs. STRATEGIC • Transferring technology to the productive sector. • Providing ongoing training to researchers. • Participating in Catalan biomedical research coordination policies. OBJECTIVES • Participating in national and international research projects and networks of excellence. • Conducting translational research with repercussions for clinical activities. • Offering high-level scientific and technological equipment and infrastructure. The strategic objectives of IIB Sant Pau cover quality biomedical research, collaboration with public and private healthcare actors, innovation and internationalisation. Furthermore, IIB Sant Pau is committed to: • Cooperation with leading international research groups conducting research in socially relevant specialty areas and treatments. • Development of state-of-the-art infrastructure, services and technologies aimed at achieving high-valueadded outcomes. • Provision of modern, well-equipped premises to foster the creation of an ecosystem of synergies between IIB Sant Pau and other research centres, technology centres and private sector enterprises, with the ultimate aim of fostering public-private partnerships. • Development of research projects with social and economic repercussions and that foster the use of innovative technologies. groups accredited by the IIB Sant Pau External Scientific Committee 70 scientifically productive groups 175 7 active research projects + 400 462 doctoral dissertations scientific-technical platforms supporting high-level research Molecular, Genomic, Cellular and KineticDynamic Bases for Diseases and their Treatment 88 82 28 91 12 654.58 352.980 119.794 279.746 65.267 Cardiovascular Diseases 46 120 251.137 538.918 accredited group publications with an impact factor researchers 13 6 Epidemiology, Public Health and Healthcare Services Haematological and Oncological Disorders thematic areas mean accumulated 49 Neurological and Mental Disorders Urology, Nephrology and Experimental Surgery Genetic, Metabolic and Inflammatory Diseases 2,448 4.78 impact factor 118 Clinical Research Ethics Committee-authorised clinical trials with drugs 11.2 €m (approximately) in revenues from activities Data of 2010 SCIENTIFIC ACTIVITIES IIB Sant Pau makes a wide range of scientific and technological services available to the scientific and business communities, as follows: • The Centre for Drug Research (CIM Sant Pau) , which has 600 m2 of premises available for initial phase I and II clinical trials, is included in the Spanish Network of Clinical Research Infrastructures (CAIBER) composed of 40 hospitals (including the HSCSP). Around 15 clinical trials are conducted each year on behalf of national and international pharmaceutical companies. • Scientific-technical platforms , with their own management and fee structures, offering confocal and fluorescence microscopy, genomics, proteomics, transcriptomics, cytometry, immunohistochemistry, biobank and in vivo experimental services. • An imaging platform, the result of a scientific alliance with Philips Healthcare, making available the latest nuclear magnetic resonance and nuclear medicine technology for patient care and research purposes. SERVICES • A neurophysiology platform, permitting in-depth exploration of spontaneous and evoked neurophysiological activity, neurophysiological reactivity and sleepwake disorders. Shortly to come online is a clean room for the Sant Pau IIB scientific community, designed for use in advanced cell therapy trials and gene therapy. IIB Sant Pau has recently established its own innovation unit to facilitate technology transfer and promote cooperation with industry. i2 HEALTH Sant Pau INNOVATION HSCSP was selected by the Ministry of Science and Innovation in 2009 as one of 14 hospitals to be included in the ITEMAS innovation network, aimed at promoting a more market-driven biomedical research model that focuses on added-value healthcare products and services. In 2010, IIB Sant Pau, along with the i2Cat Foundation, launched i2 Health Sant Pau (www.i2healthsantpau.eu) as an open innovation centre for information technologies applied to health and dependency. This project is funded by Plan Avanza and the Spanish Ministry of Industry, Tourism and Trade. i2 Health Sant Pau, which uses the Living Lab methodology, has 400 m2 of space available to accommodate development projects for marketable products and services, supported by ad hoc teams of doctors, engineers, patients and others, and funded through public calls or through cooperation with the private sector or healthcare authorities. In addition, i2Health Sant Pau intends to award innovation grants of its own, open to the entire scientific community for projects to be selected on the basis of evaluation by an advisory committee. IIB Sant Pau currently has licensing agreements for patents with four biotech companies (Genetrix, Athena Diagnostics, Digna Biotech and Nanotargets SL), is processing a further four patent applications for 2011 and has launched the first spinoff backed by HSCSP researchers (Argon Pharma SL). In 2011, the architects Buxadé-Margarit-Ferrando (2BMF) and Pich-Aguilera and the engineers JG Associats were awarded the construction project for the new IIB Sant Pau research, development and innovation buildings. THE FUTURE This project, which will enable the concentration and rationalisation of research resources, will be implemented in two phases. Phase 1 will include most of the IR-1 building (15,500 m2) to be located on the corner of C/Cartagena and C/Mas Casanovas, and also the IR-2 building (2,100 m2), to be located on C/Sant Quintí and to include underground parking for 260 vehicles. Phase 2 will see construction of the remaining part of IR-1 (6,000 m2), the entire IR-3 building (4,500 m2) and an extension to IR-2. The HSCSP Private Foundation will be in charge of financing this project. Work on phase 1, which will begin in the last quarter of 2012, will be mainly financed through a loan from the Council of Europe Development Bank. With its new premises and facilities, IIB Sant Pau will be able to increase its research activity, gain critical mass, attract talent and strengthen its leading position as a producer of quality science. The new premises will also foster the development of more translational, innovative and collaborative research and, in particular, research that is more attractive to different public and private actors involved in biomedical research. The new premises will also enable IIB Sant Pau to further develop the portfolio of services it currently offers. The CIM Sant Pau, for example, will have its own clinical trials consultation area and will be able to diversify in the oncology and biotech areas along the entire value chain. In the light of its commitment to innovation, IIB Sant Pau is especially interested in attracting technology companies. While the new buildings are being prepared, the HSCSP premises will be adapted to accommodate new projects in the research, development and innovation areas. Sant Pau Biomedical Resarch Institute Sant Antoni Maria Claret, 167 08025 Barcelona iib@santpau.cat Institut de Recerca